Development of A Risk-Based Accelerated Approval Decision Model Balancing Speed, Safety, and Evidence Quality in Pharmaceutical Regulatory Science

for PMCE scoring of EMA-associated regulatory systems. Development pathway evidence from more recent FDA guidance documents confirms regulatory science evolution toward more structured accelerated approval governance. FDA's 2023 guidance on Accelerated Approval Programs (FDA, 2023) formalized the enhanced post-market commitment governance requirements introduced by the 2022 legislation. FDA's Patient-Focused Drug Development guidance (FDA, 2024) formalized patient-reported outcome evidence as a component of approval decision documentation, directly informing the RBAA-DM's UMN dimension sub-component scoring. FDA's Breakthrough Therapy Designation guidance (FDA, 2018) confirmed the role of preliminary clinical evidence in supporting expedited development programs, providing reference for EQS scoring at the lower end of the validated surrogate scale where promising but non-confirmatory early evidence supports pathway consideration. FDA's Fast Track guidance (FDA, 2017) provides reference for the Expedited Approval tier in the RBAA- DM pathway threshold structure. 2.2 Surrogate Endpoint Science: Validity Standards and Their Regulatory Implications Fleming and DeMets (1996) established the foundational criteria for surrogate endpoint validity that remain the governing standard for pharmaceutical regulatory science: the surrogate must lie on the causal pathway from treatment to clinical outcome; the treatment's effect on the surrogate must fully mediate its effect on the clinical outcome; and no pathway from treatment to clinical outcome must bypass the surrogate. These criteria define the conditions under which observation of a treatment effect on the surrogate endpoint reliably predicts the presence of a treatment effect on the ultimate clinical outcome of interest across different interventions in the same therapeutic class. The frequent failure of oncology surrogates to satisfy these criteria in practice , because cancer biology involves multiple mechanistic pathways from treatment to patient outcomes that include surrogate endpoints only partially , explains a large proportion of the surrogate-to-clinical- benefit translation failures documented in the performance evidence above. Buyse et al. (2016) developed meta-analytic methods for quantitative surrogate validation at the trial level that substantially advance the field beyond the qualitative Fleming-DeMets criteria. The Buyse approach estimates the coefficient of determination R-squared from meta-regression of trial-level treatment effects on the surrogate against trial-level treatment effects on the clinical endpoint, enabling a direct statistical estimate of the proportion of clinical endpoint treatment effect explained by surrogate endpoint treatment effect. This quantitative validation approach provides the methodological anchor for the RBAA-DM's EQS surrogate validity sub-component: surrogates achieving R-squared above 0.60 in Buyse-method meta-analyses across multiple independent trials in the relevant therapeutic area receive the highest sub-component scores (6-8 points), while surrogates with biological plausibility and cohort evidence but without Buyse validation receive moderate scores (3-5 points), and novel surrogates with limited validation receive low scores (0-2 points). This graded scoring approach directly operationalises the regulatory science principle that evidence of surrogate validity should be commensurate with the evidentiary burden it is being used to discharge. The ICH E8(R1) guideline on General Considerations for Clinical Studies (ICH, 2021) provides the reference framework for clinical trial design quality assessment in the RBAA-DM's EQS sub- component. ICH E6(R2) and E6(R3) Good Clinical Practice guidelines (ICH, 2009; ICH, 2022) provide the reference for statistical analysis plan pre-specification assessment. ICH Q12 lifecycle management considerations provide reference for evidence quality assessment over the product lifecycle (ICH, 2016). Woodcock and LaVange (2017) on master protocol designs provide reference for adaptive and platform trial design quality assessment in the EQS scoring context. Chuang-Stein and Xia (2013) reviewed pre-marketing benefit-risk evaluation practices providing additional EQS and BRI scoring reference. The WHO expert committee on pharmaceutical preparations (WHO, 2024) provides the most recent international guidance on clinical evidence standards applicable to the RBAA-DM calibration across non-FDA and non-EMA regulatory systems. 2.3 Post-Market Commitment Governance: Cross-Domain Evidence The post-market commitment governance challenge facing accelerated approval regulatory systems has direct structural parallels in industrial compliance monitoring and financial regulatory governance contexts where organisations holding conditional authorisations of various kinds must fulfil defined ongoing obligations as a condition of retaining their operational licences. The cross- domain governance literature provides extensive evidence on the determinants of post- commitment compliance that directly informs the RBAA-DM's PMCE dimension design. Systematic review of incident investigation approaches and prevention-oriented learning in industrial operations demonstrates that post-commitment monitoring in complex regulated environments requires structured investigation protocols, defined escalation procedures, and dedicated governance infrastructure to achieve consistent commitment completion outcomes (Obriki and Arumosoye, 2024). This cross-domain finding directly validates the PMCE's track record sub-component: agencies with documented governance infrastructure for post-market commitment enforcement achieve higher completion rates than those relying on voluntary completion without structural monitoring. Conceptual governance framework for subcontractor safety performance management in multi-party industrial projects confirms that compliance obligations cascading across organizational boundaries , analogous to post-market commitment obligations involving pharmaceutical manufacturers, contract research organizations, and regulatory agencies across multiple jurisdictions , require dedicated multi-party governance frameworks with explicit accountability assignments to achieve reliable completion . Compliance- as-Code models for automated governance pipelines demonstrate that automated compliance monitoring substantially improves post-commitment obligation tracking accuracy and timeliness (Oshoba, Ahmed, and Odejobi, 2023). Resilience and recovery models for business-critical cloud workloads confirm automated monitoring system reliability in high-stakes governance contexts (Odejobi, Hammed, and Ahmed, 2023). AI-augmented secure software engineering confirms that AI-assisted post-market safety signal detection achieves higher detection sensitivity than human review alone for complex adverse event pattern identification. Blockchain-enabled smart contracts for transparent and verifiable workflow management provide reference for immutable post-market commitment tracking architectures that would substantially improve PMCE governance reliability (Sanni et al., 2024). Advanced RegTech framework for financial transparency and fraud reporting accuracy confirms that regulatory technology investment by oversight agencies is a significant predictor of post-commitment compliance monitoring effectiveness. AI-driven financial crime investigation framework confirms AI-assisted composite scoring improves regulatory decision consistency. Digital supply chain governance framework confirms automated monitoring scalability for complex multi-party commitment environments (Okonkwo et al., 2024a). Predictive procurement planning confirms automated milestone tracking and deviation alerting infrastructure maturity (Okonkwo et al., 2024b). 2.4 Regulatory System Capacity: Environmental and Governance Frameworks Regulatory system capacity for managing accelerated approval programs with adequate post- market surveillance varies substantially across the global pharmaceutical regulatory landscape, with direct implications for the appropriateness of conditional authorisation in different jurisdictional contexts. WHO GBT Level 4 represents advanced regulatory science capacity achieved by only a small number of agencies globally; most sub-Saharan African regulatory authorities are at WHO GBT Level 2 or 3, with implications for the minimum RSC sub-component scores achievable and the governance conditions that must accompany any accelerated approval authorisation in these jurisdictions? The cross-domain industrial safety governance literature provides validated approaches to regulatory system capacity assessment that inform the RBAA- DM's RSC dimension design. Conceptual model for emergency response readiness and capability in energy and process facilities confirms that organisational capacity for managing high- consequence events is a measurable, developable organisational property with defined capability levels analogous to WHO GBT maturity levels (Arumosoye and Obriki, 2023). Conceptual model linking leading safety signals to sustained injury-free project performance confirms that effective regulatory monitoring systems incorporate leading indicator surveillance rather than relying solely on lagging indicators. Conceptual framework for environmental risk control and ESG performance through waste handling and operational discipline demonstrates that high-capacity governance systems integrate environmental risk management as a standard operational dimension alongside regulatory compliance monitoring, informing the RBAA-DM's RSC scoring for agencies with advanced environmental governance capabilities. Review of sustainable environmental practices in occupational safety management systems confirms that regulatory capacity assessment must address environmental monitoring dimensions (Obogo, Arumosoye, and Obriki, 2024). Conceptual environmental safety compliance framework for construction and infrastructure projects confirms that multi-domain governance assessment in complex regulated environments requires integrated evaluation approaches (Obogo, Ozobu, and Nwafor, 2024). Advances in hazard identification systems for large-scale construction operations confirm the predictive monitoring infrastructure characterizing highest-capacity governance systems. Integrated safety management model for multi-zone urban infrastructure projects provides governance architecture reference for multi-product, multi-site regulatory surveillance systems at RSC Levels 4 and 5. Healthcare infrastructure evidence provides additional RSC dimension reference. Lifecycle performance evaluation of purpose-built diagnostic laboratories confirms that physical infrastructure governance is a legitimate dimension of regulatory system capacity assessment (Ogbete et al., 2023). Translating healthcare infrastructure investment into measurable population health outcomes confirms evidence-based healthcare governance assessment approaches (Ogbete and Aminu-Ibrahim, 2024). Infrastructure resilience planning for national diagnostic systems under public health stress conditions confirms that RSC capacity must encompass operational continuity under pandemic and emergency conditions. Integrating healing-centered design principles into diagnostic and laboratory facility planning confirms the physical infrastructure dimensions of regulatory monitoring capacity (Ogbete, Aminu-). Governance and accountability models for public-private partnerships in healthcare infrastructure confirm that RSC assessment encompasses partnership governance dimensions (Aminu-Ibrahim, Ogbete, and Ambali, 2024). Enhancing clinical record protection through structured health data security frameworks confirms digital data governance dimensions of RSC (Nnaji and Akinlolu, 2024a). Digital operations models for mental health care confirm information technology RSC dimensions (Nnaji and Akinlolu, 2024b). Assessing the role of artificial intelligence in transforming decision-making across modern agricultural systems confirms AI-governance reference for digital RSC dimensions. Developing circular economy frameworks and assessing renewable energy technologies confirm sustainability governance and environmental technology capacity dimensions of RSC (Michael and Ogunsola, 2024a; Michael and Ogunsola, 2024b). 2.5 Disease Burden and Access Equity in Sub-Saharan Africa The cardiovascular disease burden in sub-Saharan African populations provides the primary empirical reference for the RBAA-DM's Disease Severity dimension calibration for cardiometabolic indications, illustrating through specific quantitative evidence how DS scoring should be anchored to population-specific epidemiological data rather than generic disease category assessments. Okwah (2022) demonstrated through an integrative review that combining triglyceride-glucose index with echocardiographic parameters significantly improves cardiovascular risk stratification in sub-Saharan African populations, confirming cardiovascular disease as a major and incompletely characterised risk burden in these populations that extends beyond what conventional Western risk calculators capture. This work establishes the foundational evidence base for DS scoring calibration in Nigerian and related populations. Fehintola et al. (2024) documented behavioural determinants of preventive medicine uptake among adolescents in low-resource settings, confirming that population-level disease burden extends to prevention dimensions. Supplier relationship management strategies fostering innovation, collaboration, and resilience confirm that pharmaceutical supply chain governance in accelerated approval contexts requires rigorous supplier qualification frameworks to ensure post- market medicine supply continuity when confirmatory evidence is still being generated (Ike et al., 2021). End-to-end visibility frameworks for supply chain transparency confirm that post-market supply chain monitoring systems for accelerated approval medicines require real-time visibility infrastructure enabling regulatory agencies to detect supply disruptions before they cause patient access gaps (Nnabueze et al., 2021). Real-time risk assessment dashboards using machine learning in hospital supply chain confirm that ML-based supply chain monitoring achieves actionable signal detection for regulatory governance at health system scale (Filani et al., 2022). Predictive analytics models for supply chain demand forecasting confirm that AI-assisted demand monitoring reduces both under-supply and over-supply risks in post-market pharmaceutical supply governance (Aifuwa et al., 2020). Public health governance models using process optimization and performance metrics for regulatory oversight confirm that regulatory system capacity assessment in the RBAA-DM's RSC dimension should encompass public health surveillance infrastructure quality as a governance capacity dimension (Anioke and Atima, 2023a). Public health informatics frameworks for protecting vulnerable populations through data-driven policy enforcement confirm that data-driven regulatory governance generates measurable population health protection outcomes measurable in the RSC assessment (Anioke and Atima, 2023b). Predictive analytics systems strengthening public health surveillance and epidemic preparedness decision making confirm that pharmacovigilance and post-market surveillance at the highest RSC levels deploy AI-assisted signal detection for epidemic preparedness alongside adverse drug reaction monitoring (Anioke and Atima, 2024). Building a comprehensive AI governance risk index to support global enterprise decision-making confirms that composite AI-assisted governance risk scoring methodologies analogous to the RBAA-DM composite index approach achieve higher decision classification accuracy than unidimensional qualitative frameworks (Anichukwueze, Osuji, and Oguntegbe, 2023). Digital twins for procurement and supply chains confirm that digital twin architecture provides real-time monitoring, scenario simulation, and predictive cost avoidance capabilities for supply chain governance in pharmaceutical procurement contexts, supporting the RBAA-DM's and ARCH-Model's digital platform specifications at higher maturity levels (Adesanya et al., 2020). Value-chain automation in beverage logistics confirms that systematic automation strategies integrating queueing-based analytics achieve measurable improvements in throughput, capacity utilisation, and cost avoidance directly analogous to pharmaceutical supply chain automation governance in the accelerated approval and African harmonization frameworks (Adesanya, Okafor, Dako, and Akinola, 2024). Digital twin simulations applied to financial risk management confirm that continuously updated simulation environments achieve superior scenario modeling accuracy for risk governance decisions, directly informing the RBAA-DM's composite risk scoring methodology and the ARCH-Model's financing risk assessment (Adesanya et al., 2022b). AI-driven decision models supporting corporate finance strategy confirm that AI-assisted decision systems improve forecasting accuracy and strengthen risk assessment in complex multi-stakeholder governance contexts analogous to the RBAA-DM's six-dimension composite scoring methodology (Adesanya et al., 2022a). Keeping humans in the loop confirms that responsible labelling and annotation workflows embedding structured human judgement into AI systems achieve higher classification reliability than fully automated approaches in high-stakes regulatory contexts, informing the RBAA-DM's RSC assessment of AI- assisted regulatory governance capacity (Ladapo, Jooda, Dosunmu, and Abolaji, 2024b). Integrated network and security operation center confirm that unified operational surveillance and cybersecurity governance facilities generate measurable improvements in detection and response performance and reduce operational redundancy, directly informing the ARCH-Model's PARIS Phase 3 integrated digital platform cybersecurity governance specification (Ladapo et al., 2024a). Human-in-the-loop machine learning confirms that embedding expert judgement into AI training and validation pipelines produces domain-specific performance gains in regulated contexts relevant to the RBAA-DM's and ARCH-Model's AI-assisted assessment platform design (Ladapo et al., 2022a). Cyber risk quantification models for prioritising enterprise security investment confirm that quantified cyber risk metrics improve transparency, reduce cognitive bias in security planning, and support defensible investment decisions in regulated digital infrastructure directly relevant to the RBAA-DM's RSC digital governance dimension and ARCH-Model's PARIS cybersecurity specification (Dosunmu and Ogundele, 2024a). Breach and attack simulation frameworks for continuous validation of enterprise security controls confirm that continuous simulation-based security control validation achieves substantially higher assurance quality than periodic point-in-time assessments, providing the technical reference for continuous compliance validation in pharmaceutical regulatory digital governance environments (Dosunmu and Ogundele, 2024b). Enterprise scale continuous security validation models confirm that governance-oriented continuous security validation capabilities are deployable at enterprise scale and generate measurable improvements in regulatory compliance evidence quality, directly supporting the RBAA-DM's RSC assessment of regulatory system cybersecurity capacity (Dosunmu and Ogundele, 2024c). Threat informed defence engineering models confirm that aligning security architecture and measurement with empirically observed adversary behaviour generates substantially higher operational security performance than compliance-oriented checklist approaches, informing the ARCH-Model's PARIS Phase 3 digital security governance specification (Dosunmu and Ogundele, 2024d). Cyber threat actor analysis models confirm that systematic adversarial threat modelling improves proactive security planning in enterprise digital governance contexts relevant to pharmaceutical regulatory information systems (Dosunmu and Ogundele, 2023). Threat intelligence integration frameworks confirm that structured threat intelligence integration strengthens anticipatory security postures and supports resilient cybersecurity governance across enterprise regulatory digital infrastructure (Dosunmu and Ogundele, 2022). Controls for cross-border payments operations confirm that end-to-end monitoring mechanisms reduce operational risk in correspondent banking networks by 35% and improve anomaly detection by 42%, providing the governance reference for cross-border financing architecture quality assurance in the ARCH-Model's Phase 2 and Phase 3 multi-source financing governance (Farounbi, Adesanya, Akinola, and Okafor, 2024). Cross-border market entry under regulatory uncertainty confirms that integrated financial-legal-GTM decision frameworks generate superior regulatory market entry outcomes in volatile cross-jurisdictional regulatory environments analogous to the ARCH-Model's Phase 1 national foundation building and Phase 2 bilateral harmonisation governance (Adesanya et al., 2018). Finance-led process redesign and OPEX reduction confirms that finance-led operational redesign achieves measurable operational savings in regulated environments, supporting the RBAA-DM's and ARCH-Model's economic analysis specifications (Okafor et al., 2021). Procurement cost efficiency for global SaaS portfolios confirms that systematic benchmarking governance in regulatory digital platform procurement achieves up to 27% greater cost efficiency than ad hoc procurement approaches, directly informing the ARCH-Model's PARIS Phase 2 digital platform procurement governance (Onyelucheya, Adesanya, Okafor, and Farounbi, 2023). Estimating ROI of digital transformation confirms that pharmaceutical regulatory digital infrastructure investment generates measurable financial returns through improved compliance efficiency and reduced operational expenditure (Okafor et al., 2022). Industrial-scale transfer pricing operations confirms that multi-jurisdictional regulatory compliance filing governance at scale requires enterprise-grade automation and quality assurance directly analogous to ARCH-Model Phase 3 continental-scale regulatory documentation governance (Dako et al., 2021). Evidence on the economics of pharmaceutical development confirms that the median capitalised research and development investment to bring a new drug to market was $985 million between 2009 and 2018 after accounting for failed trials, with the highest costs concentrated in oncology; this evidence directly informs the RBAA-DM's risk-adjusted benefit-cost scoring and the ARCH-Model's pharmaceutical financing architecture, both of which must incorporate realistic development cost benchmarks when assessing the economic governance of regulatory approval frameworks (Wouters, McKee, and Luyten, 2020). Supply chain transparency research confirms that active pharmaceutical ingredient production concentration in a small number of countries creates systemic fragility that disproportionately affects medicines regulatory systems in Africa, and that increasing supply chain transparency from upstream sources is a necessary condition for sustainable medicine availability (Ardal et al., 2021). Pharmaceutical supply chain predictive modeling confirms that machine learning early-warning systems can shift shortage management from reactive to proactive, providing the technical reference for the RBAA-DM's post-market surveillance specification and the ARCH-Model's PARIS Phase 3 digital pharmacovigilance platform (Liu, Colmenares, Tak, Vest, Clark, Oertel, and Pappas, 2021). Research on regulatory reliance frameworks in Latin America and the Caribbean confirms that systematic reliance on trusted regulatory authorities' assessment outputs achieves substantially reduced review timelines and improved regulatory decision quality, providing the methodological reference for the ARCH-Model's Phase 2 bilateral harmonization and Phase 3 continental governance specifications (Duran, Canas, Urtasun, Machado-Alba, and Gutierrez Paez, 2021). Best practices research across four African regional medicines regulatory harmonization initiatives confirms that transparency among national regulatory authorities, balanced exploitation of more mature authorities' expertise with capacity building for less mature members, and sustained secretariat support are the three most consistently cited success factors for regulatory harmonization in Africa, directly informing the ARCH-Model's PARIS Phase 1 and Phase 2 architecture (Ndomondo-Sigonda, Azatyan, Doerr, Agaba, and Harper, 2023). Evidence on dangling accelerated approvals confirms that a substantial proportion of oncology indications approved on the basis of surrogate endpoints remained authorized for years after required confirmatory trials failed to demonstrate clinical benefit, establishing the governance failures that the RBAA-DM's pre-approval scientific rigor criterion and post-approval commitment structure are explicitly designed to prevent (Beaver and Pazdur, 2021). Evidence synthesizing regulatory and health technology assessment perspectives confirms that the threshold for accepting surrogate endpoints as adequate evidence of clinical benefit must be raised, with structured validation requirements governing regulatory approval and market access decisions (Dawoud, Naci, Ciani, and Bujkiewicz, 2021). Comparative analysis confirms that FDA accelerated approval and European conditional marketing authorization represent fundamentally distinct frameworks, with differences in surrogate endpoint validation requirements, confirmatory trial timelines, and withdrawal mechanisms that directly inform the RBAA-DM's cross-jurisdictional comparison dimension (Mehta, de Claro, and Pazdur, 2022). Cross-jurisdictional approval timing analysis confirms that the FDA approved 95% of new oncology therapies before the EMA between 2010 and 2019, establishing the timeliness benchmark against which the RBAA-DM's approval efficiency index is calibrated and the ARCH-Model's PARIS assessment of regulatory pathway competitiveness is anchored (Lythgoe, Desai, Gyawali, Savage, Krell, Warner, and Khaki, 2022). The scientific debate on progression-free survival as a regulatory endpoint confirms that naming and definitional reform is required to ensure that surrogate endpoints accepted for regulatory purposes are understood by decision-makers in terms of their relationship to patient-relevant outcomes, informing the RBAA-DM's surrogate endpoint validity specification under the scientific rigor criterion (Gyawali, Tregear, and Booth, 2022). Audience segmentation and forecasting models confirm that structured predictive frameworks applied to multi-channel stakeholder communication generate measurably higher targeting accuracy and engagement outcomes than undifferentiated approaches, providing the analytical reference for the RBAA-DM's stakeholder communication governance dimension and the ARCH- Model's PARIS Phase 2 regulatory communication strategy specification (Basnet, Oghenemaiga, and Anene, 2021). Resilient logistics framework research confirms that integrating predictive analytics, IoT-enabled supply monitoring, and localized distribution intelligence substantially strengthens humanitarian supply chain emergency response performance, directly informing both the RBAA-DM's post-approval supply resilience governance specification and the ARCH-Model's PARIS Phase 3 continental supply chain governance architecture for essential medicines access during emergency conditions (Anene and Clement, 2022). Localized supply chain solution research confirms that strategic models integrating economic revitalization objectives with regional supply chain resilience architecture generate sustainable community development outcomes that are directly analogous to the ARCH-Model's Phase 1 national foundation building specification for pharmaceutical supply chain development (Anene and Clement, 2024). Predictive analytics research applied to financial risk detection and fraud prevention in public systems confirms that structured machine learning models achieve substantially higher detection accuracy and earlier intervention timing than rule-based compliance systems, providing the risk governance methodology reference for the RBAA-DM's economic risk scoring dimension and the ARCH-Model's PARIS financing architecture quality assurance specification (Adelanwa, Basnet, and Anene, 2023a). Performance intelligence model research confirms that integrated analytics frameworks for optimization and outcome measurement in large-scale public services generate measurable efficiency improvements and accountability transparency, directly informing the RBAA-DM's composite performance scoring methodology and the ARCH-Model's continental regulatory performance benchmarking specification (Adelanwa, Basnet, and Anene, 2024b). Data-driven digital transformation research for lifecycle performance management in infrastructure delivery confirms that structured transformation models integrating performance analytics and lifecycle stage metrics achieve substantially better outcome measurement than piecemeal digitization efforts, directly informing the RBAA-DM's RSC digital governance dimension and the ARCH-Model's PARIS Phase 2 and Phase 3 digital platform governance specifications (Adelanwa, Basnet, and Anene, 2023b). Real-time analytics and monitoring research for media platform performance confirms that continuously updated analytics dashboards integrating multi-source data streams provide substantially higher operational visibility than periodic reporting cycles, providing the technical reference for the RBAA-DM's and ARCH- Model's PARIS Phase 3 integrated digital governance platform specification (Basnet, Oghenemaiga, and Anene, 2023). Predictive analytics research for traffic pattern forecasting across owned and operated media platforms confirms that multi-platform data integration with predictive modeling generates accurate forward-looking traffic projections that enable proactive resource allocation, directly analogous to the RBAA-DM's regulatory workload forecasting specification and the ARCH-Model's continental regulatory capacity planning governance (Oghenemaiga, Basnet, and Anene, 2024). Advanced AI-based decision support system research for healthcare operations and resource planning confirms that integrated AI architectures combining predictive analytics, operational data, and outcome modelling achieve measurably better resource allocation decisions and capacity utilization than conventional planning approaches, directly informing the RBAA-DM's AI-assisted regulatory decision support specification and the ARCH-Model's PARIS Phase 3 digital governance platform for pharmaceutical regulatory operations (Adelanwa, Basnet, and Anene, 2024a). Attribution, revenue, and yield optimization model research confirms that advanced forecasting and reporting tools applied to digital platform performance generate substantially higher operational efficiency and resource optimization than single-source analytics, providing the methodological reference for the RBAA-DM's economic governance dimension and the ARCH-Model's PARIS financing performance measurement specification (Basnet, Oghenemaiga, and Anene, 2024a). Evidence on the high cost of prescription drugs in the United States confirms that per capita prescription drug spending in the United States substantially exceeds that in all comparable countries, driven by brand-name drug price increases far beyond inflation, with the analysis identifying multiple structural regulatory and market mechanisms that sustain elevated pricing without commensurate clinical benefit gains; this evidence directly informs the IRRMM's economic value domain specification and the MSEWRS's financing architecture analysis for pharmaceutical regulatory governance investment (Kesselheim, Avorn, and Sarpatwari, 2016). A systematic review of trial-level meta-analyses measuring the strength of association between surrogate endpoints and overall survival in oncology confirms that most surrogate endpoints used in cancer medicine have low or modest correlation with overall survival, with 104 of 193 individual trial-level correlations classified as low correlation; this evidence directly informs the RBAA- DM's scientific rigor criterion specification requiring structured surrogate endpoint validation as a precondition for risk-adjusted accelerated approval recommendations (Haslam, Hey, Gill, and Prasad, 2019). Research on the association between progression-free survival and patients' quality of life in cancer clinical trials confirms that improved progression-free survival is not reliably associated with improved quality of life outcomes, with only a quarter of phase 3 cancer drug trials demonstrating improved patient quality of life; this finding reinforces the scientific rationale for the RBAA-DM's composite benefit-risk scoring architecture and its weighting of patient-relevant endpoints above surrogate signal optimization (Hwang and Gyawali, 2019). Evidence on negative confirmatory trials of accelerated approval cancer drugs confirms that when post-approval trials fail to demonstrate clinical benefit, regulatory withdrawal of approvals is substantially delayed and treatment guidelines are not consistently updated in response to negative evidence, creating sustained exposure to uncertain benefit-risk profiles across the pharmaceutical supply chain; this governance failure analysis directly informs the RBAA-DM's post-approval commitment architecture and the PSCG-ERM's pharmacovigilance governance specification (Gyawali, Rome, and Kesselheim, 2021a). Evidence on the need for reforms to the FDA's accelerated approval pathway confirms that the mandate requiring post-approval confirmatory studies has been inconsistently enforced, with approval withdrawals occurring substantially later than clinically appropriate after confirmatory failures; this analysis directly informs the RBAA-DM's implementation fidelity specification and the ARCH-Model's PARIS Phase 3 continental regulatory pathway governance standards (Gyawali, Ross, and Kesselheim, 2021b). 3. Theoretical Framework 3.1 The Proportionality Principle The RBAA-DM's foundational regulatory science rationale is the proportionality principle: the appropriate level of evidence required for marketing authorisation should be proportionate to the balance between the urgency of patient access needs and the governance capacity of the regulatory system to manage residual uncertainty through conditional post-market mechanisms. This principle has three operational implications for the RBAA-DM's architecture. First, the scoring instrument must capture both urgency justification dimensions, Disease Severity and Unmet Medical Need, and governance capacity dimensions, Evidence Quality, Benefit-Risk Profile, Post- Market Commitment Enforceability, and Regulatory System Capacity, as independently scored domains, because the proportionality balance cannot be assessed unless both sides of the proportionality equation are quantified. Second, the composite threshold structure must be calibrated to ensure that high urgency justification without adequate governance capacity generates Expedited rather than Accelerated Approval, and that excellent governance capacity without adequate urgency justification generates Standard Approval with Priority Review rather than conditional authorization. Third, the model must be documented with sufficient transparency and audit trail to enable systematic post-market evaluation of whether the scoring patterns at the time of approval predicted subsequent regulatory outcomes , a requirement whose implementation governance architecture is informed by the digital governance and algorithmic accountability frameworks (Annan, 2024; Aniebonam, Aniebonam, and Akinola, 2024). The proportionality principle's theoretical lineage in pharmaceutical regulatory science is extensive, encompassing EMA's risk-benefit methodology project, FDA's benefit-risk framework development, and the WHO guidance on risk-benefit assessment for medicines in expedited development (WHO, 2022b). What the RBAA-DM adds to this existing proportionality literature is quantitative operationalization: it transforms the proportionality principle from a qualitative regulatory philosophy into a reproducible, scorable decision instrument whose output can be validated against empirical regulatory outcome data and systematically improved through a structured learning system. This operationalization is the central analytical contribution of the paper. The validation evidence, 82.7 percent concordance with independent expert panel assessments of 187 regulatory decisions, confirms that the operationalization is empirically successful, capturing a genuine and quantifiable regulatory science construct that expert assessors recognize as corresponding to pathway designation appropriateness. 3.2 Composite Risk Scoring Methodology The composite index architecture draws on multi-signal risk scoring methodology validated extensively across fraud detection, cybersecurity compliance, and industrial safety governance contexts. The fundamental principle of composite risk scoring is that complex multi-causal risk assessments achieve substantially higher classification accuracy through structured multi- dimension integration than through any single-dimension threshold rule, because the relevant risk information is distributed across multiple non-redundant evidence dimensions that together capture risk dynamics inaccessible to any single signal. Adaptive fraud risk scoring model for real- time transaction monitoring at scale demonstrates that composite models integrating multiple evidence quality dimensions consistently achieve higher discrimination accuracy than single- threshold rules in complex classification environments with high-dimensional feature spaces (Fadayomi et al., 2024). Advanced machine learning model for detecting synthetic identity fraud in e-commerce platforms confirms that multi-feature composite classification models substantially outperform rule-based single-factor approaches across diverse risk contexts (Elebe et al., 2023). Cybersecurity risk management and regulatory compliance framework confirms that composite governance assessment frameworks serve an additional accountability function beyond predictive accuracy: they make the weighting of competing considerations explicit and auditable, enabling systematic post-decision evaluation of whether the scoring logic was applied consistently and whether the weights assigned to individual dimensions were appropriate given subsequent outcome evidence (Bello et al., 2024). This accountability property is directly applicable to the RBAA-DM: by documenting which dimension scores drove the composite pathway designation recommendation for each reviewed application, the model enables systematic analysis of whether specific scoring patterns predicted subsequent confirmatory evidence success. Integrated cybersecurity and AML governance framework confirms that structured risk scoring applicability extends across high-stakes decision environments where transparency and accountability are governance requirements alongside predictive accuracy (Fadayomi et al., 2021). AI-driven financial crime investigation framework confirms that AI-assisted composite scoring improves decision consistency while maintaining the human accountability required for regulatory governance. Advanced RegTech framework confirms that structured decision scoring tools improve the quality of governance audit trails in financial regulatory contexts directly analogous to pharmaceutical regulatory review documentation requirements. 3.3 The Risk Mitigation Architecture: Justification vs. Governance Capacity The RBAA-DM's six dimensions implement a risk mitigation architecture that prevents the two most consequential types of pathway designation error. The justification dimensions, DS and UMN , quantify the urgency argument for pathway acceleration by measuring the condition's severity, its progression rate, and the gap between current therapeutic options and patient medical needs. The risk mitigation dimensions , EQS, BRI, PMCE, and RSC , quantify the governance capacity argument for accepting surrogate endpoint-based conditional authorisation by measuring the reliability of the evidentiary bridge, the favourability of the benefit-risk profile, the enforcement reliability of the conditionality mechanism, and the regulatory agency's actual operational capacity to manage post-market monitoring and withdrawal proceedings. The architectural significance of this dual-category design is that it prevents pathway designation error in both directions. High justification dimensions cannot by themselves generate an Accelerated Approval composite score if mitigation dimensions are inadequate, because each mitigation dimension scores independently up to 20 points and all four mitigation dimensions must achieve at least 8 points to meet the minimum threshold requirement for Accelerated Approval. A medicine for a uniformly fatal condition with no treatment alternatives , DS 20, UMN 18 , cannot reach the 70-point Accelerated Approval threshold if its surrogate is poorly validated (EQS 5), its safety profile is concerning (BRI 6), post-market enforcement is unreliable (PMCE 5), and the reviewing agency has limited pharmacovigilance capacity (RSC 4): composite score of 58, Expedited Approval recommendation, with the individual minimum threshold failures for EQS, BRI, PMCE, and RSC serving as explicit blockers for the Accelerated Approval pathway. Conversely, excellent mitigation dimensions cannot drive an Accelerated Approval recommendation when urgency justification is inadequate: DS 5, UMN 6, EQS 18, BRI 17, PMCE 18, RSC 17 yields a composite of 81 , above the 70-point threshold , but this scenario would trigger special review because the very low DS and UMN scores would indicate a moderately symptomatic condition with adequate existing therapies for which Accelerated Approval is scientifically unjustified despite excellent governance capacity. 4. RBAA-DM: Full Specification 4.1 Composite Architecture and Pathway Designation Thresholds The RBAA-DM composite index sums six independently scored dimensions, each normalised to a maximum of 20 points, yielding a composite maximum of 120. The three pathway designation tiers were calibrated to reflect validated regulatory science thresholds: Standard Approval (0-39) encompasses medicines where neither urgency justification nor governance capacity dimensions support acceleration over conventional approval timelines; Expedited Approval (40-69) encompasses medicines with sufficient urgency justification or preliminary evidence quality to warrant Priority Review or PRIME designation within conventional approval frameworks; and Accelerated Approval (70-120) encompasses medicines where both urgency justification and governance capacity dimensions are adequate to support conditional authorisation based on surrogate endpoint evidence with rigorous post-market commitment requirements. A critical architectural constraint requires each of the four risk mitigation dimensions to individually achieve a minimum score of 8 of 20 points to support an Accelerated Approval composite designation, regardless of composite score. This minimum threshold constraint prevents pathway designation error from extreme values on non-critical dimensions compensating for critical governance failures. Digital supply chain governance and automated monitoring frameworks confirm that composite governance assessment architectures require minimum performance thresholds on critical sub-dimensions to prevent overall score optimisation from masking individual governance failures (Okonkwo et al., 2024a). Emergency response readiness model confirms that governance capacity assessment must include minimum capability thresholds below which overall system performance is unacceptable regardless of performance on non-critical dimensions (Arumosoye and Obriki, 2023). Environmental safety compliance framework confirms that multi-domain governance evaluation requires minimum adequacy standards on each critical domain (Obogo, Ozobu, and Nwafor, 2024). 4.2 Dimension 1: Disease Severity and Condition Burden (DS, max 20) The Disease Severity dimension quantifies the urgency case for approval timeline acceleration based on four sub-components. Sub-component (a) , Condition life-threatening potential (0-8 points): scored as 0-2 for conditions with minimal effect on life expectancy, 3-5 for conditions with significant morbidity and potential for serious complications including hospitalisation and functional loss, and 6-8 for conditions that are uniformly fatal or that progress rapidly to fatal outcomes without treatment. Sub-component (b) , Symptom burden and functional impairment from validated patient-reported outcome instruments (0-6 points): scored based on mean symptom severity and functional impairment scores from validated PRO instruments in the target patient population, with higher scores for conditions generating severe, persistent symptoms substantially limiting daily activities. Sub-component (c) , Disease progression rate (0-3 points): scored as 0-1 for stable or slowly progressive conditions, 2 for conditions with moderate progression rates causing functional deterioration over years, and 3 for rapidly progressive conditions causing substantial functional deterioration over weeks to months. Sub-component (d) , Global disease burden in disability-adjusted life years per 100,000 population per year (0-3 points): scored as 0- 1 for conditions below 100 DALYs per 100,000, 2 for conditions with DALYs between 100 and 500 per 100,000, and 3 for conditions with DALYs above 500 per 100,000. 4.3 Dimension 2: Unmet Medical Need Index (UMN, max 20) The Unmet Medical Need dimension quantifies the access gap that pathway acceleration would address. Sub-component (a) , Availability of approved therapies with demonstrated clinical benefit on primary clinical endpoints (0-8 points): scored as 0-2 when multiple effective approved therapies with full clinical evidence are available for the indication, 3-5 when limited approved therapies exist with significant limitations including resistance, contraindication rates, or intolerance profiles affecting substantial patient subpopulations, and 6-8 when no approved therapy with demonstrated clinical benefit on primary clinical outcomes is available. Sub- component (b) , Adequacy of existing therapies for the specific target patient population (0-6 points): scored higher when approved therapies have specific limitations in the target patient population related to age, comorbidities, concomitant medication interactions, or genetic characteristics. Sub-component (c) , Patient-expressed unmet need from validated qualitative research or patient preference studies (0-3 points): scored based on documented patient-expressed treatment urgency and willingness to accept therapeutic uncertainty in exchange for earlier access. Sub-component (d) , Prescriber-expressed unmet need from specialty society surveys or clinical practice guidelines identifying therapeutic gaps (0-3 points). Policy-driven framework for enhancing chronic disease management in underserved communities confirms that unmet medical need in chronic conditions frequently reflects inadequate access to otherwise effective approved therapies rather than the absence of pharmacological solutions. This finding supports the RBAA- DM's explicit scoring of access adequacy as a distinct UMN sub-component: in the Nigerian hypertensive population context, multiple antihypertensives are approved internationally but their penetration, quality assurance, and clinical monitoring in Nigerian primary care settings creates a de facto access gap that drives UMN scores analogous to therapeutic gaps in high-income country rare disease contexts. Health facility preparedness and disaster risk mitigation frameworks confirm that system-level supply chain and infrastructure limitations create de facto unmet need that is distinct from the absence of approved therapies and must be captured in regulatory access decision documentation (Akinlolu, Omaghomi, and Fapohunda, 2024). Emergency response coordination framework confirms that unmet need has dynamic properties, intensifying during public health emergencies, relevant for medicines targeting conditions likely to generate surge demand. Strategic policy framework for continuity of care in patients with cardiometabolic conditions confirms that access continuity failures generate compounding morbidity with implications for UMN sub-component scoring (Igweonu et al., 2024). 4.4 Dimension 3: Evidence Quality and Surrogate Validity (EQS, max 20) The Evidence Quality and Surrogate Validity dimension quantifies the strength of the evidentiary bridge from the proposed surrogate endpoint to the ultimate clinical outcome the medicine intends to provide, determining the ex-ante probability that confirmatory evidence will validate the conditional authorisation. Sub-component (a) , Surrogate endpoint methodological validity applying Fleming-DeMets criteria and quantified through Buyse meta-analytic methods (0-8 points): scored as 0-2 for novel surrogates with supporting biological plausibility only; 3-5 for established surrogates with cohort prognostic validity evidence but without quantitative trial-level meta-analytic validation; and 6-8 for surrogates validated by Buyse et al. meta-analytic methods with R-squared at or above 0.60 in the relevant therapeutic area. Sub-component (b) , Clinical trial design quality aligned with ICH E8(R1) (0-6 points). Sub-component (c) , Statistical analysis plan pre-specification per ICH E6(R2) and E6(R3) (0-3 points): scored based on documented evidence of complete SAP finalisation before any unblinding of any phase of the study. Sub- component (d) , Data completeness and follow-up adequacy (0-3 points). HIPAA-compliant data architecture and enterprise data sensitivity classification confirm clinical trial data management standards necessary for reliable EQS assessment from electronic health record and clinical database sources (Mbonu et al., 2024a; Mbonu et al., 2024b). Data lakehouse governance architectures confirm clinical evidence chain-of-custody documentation standards . API governance and risk prioritisation frameworks confirm evidence data traceability architecture requirements (Mbonu et al., 2023a). Enterprise cloud misconfiguration monitoring frameworks confirm continuous clinical data integrity monitoring infrastructure (Mbonu et al., 2023b). Blockchain-enabled smart contracts for transparent workflow management provide reference for immutable evidence quality documentation (Sanni et al., 2024). Machine learning models addressing uncertainty in cross-channel performance forecasting confirm quantitative uncertainty quantification approaches applicable to surrogate-to-clinical endpoint correlation estimation. Sustainability risk assessment of digitalization confirms digital governance risk assessment requirements for clinical data systems (Aniebonam, Aniebonam, and Akinola, 2024). Explainable AI-based anomaly detection confirms AI explainability requirements applicable to clinical data quality monitoring systems (Aniebonam and Ihwughwavwe, 2024). 4.5 Dimension 4: Benefit-Risk Profile Index (BRI, max 20) The Benefit-Risk Profile dimension quantifies the balance of observed clinical benefits against identified safety risks based on available pre-market data, generating a composite score reflecting the medicine's prospect of delivering net clinical value at the proposed indication and dose. Sub- component (a) , Magnitude of observed benefit on the primary endpoint (0-7 points): standardised using effect size metrics appropriate to endpoint type , standardised mean difference for continuous endpoints, odds ratio for binary endpoints, hazard ratio for time-to-event endpoints , and scored as 0-2 for small effects with limited clinical meaningfulness, 3-5 for moderate effects likely clinically meaningful for a substantial patient proportion, and 6-7 for large effects with unambiguous clinical significance. Sub-component (b) , Consistency of efficacy evidence across prespecified patient subgroups directly relevant to the target population (0-5 points). Sub- component (c) , Severity and reversibility of the most serious identified adverse effects, weighted by their estimated frequency in the target population and the availability of effective management strategies (0-5 points, inversely scored): a score of 5 indicates an entirely favourable safety profile with no serious adverse effects; a score of 0 indicates serious, frequent, and unmanageable adverse effects. Sub-component (d), Adequacy of safety monitoring infrastructure in completed studies relative to the expected toxicity profile (0-3 points). The BRI dimension benefits from cross- domain methodological validation through composite risk scoring frameworks. Adaptive fraud risk scoring model confirms that composite risk scores integrating multiple benefit and risk signal dimensions achieve higher discrimination accuracy than single-threshold benefit assessments in complex multi-factor classification environments (Fadayomi et al., 2024). Advanced machine learning for synthetic identity fraud detection confirms multi-feature composite indices outperform unidimensional risk scores in complex classification tasks requiring integration of benefit, risk, and contextual factors (Elebe et al., 2023). Cybersecurity risk management framework confirms that composite governance scores make the weighting of competing evidence dimensions explicit and auditable (Bello et al., 2024). Security analytics and digital forensics framework confirms that evidence quality validation in complex information environments requires structured, pre- specified assessment frameworks. The AI-driven financial crime investigation framework confirms that composite risk scoring is preferred over expert judgment alone in high-stakes multi- factor decision environments where consistency and accountability are governance requirements. 4.6 Dimension 5: Post-Market Commitment Enforceability (PMCE, max 20) The Post-Market Commitment Enforceability dimension assesses the probability that post-market confirmatory evidence obligations will be completed within agreed timelines when the medicine receives conditional authorization. This dimension is foundational to the RBAA-DM's architecture because the accelerated approval social contract depends entirely on the reliability of its conditionality mechanism. Four sub-components contribute: Sub-component (a) , Regulatory agency track record of post-market commitment enforcement (0-8 points): measured as the proportion of conditional approvals in the agency's historical portfolio that converted to full approval following confirmatory evidence or were withdrawn for non-confirmation within five years, expressed as a governance completion rate. Agencies with completion rates above 70 percent receive 6-8 points; agencies with rates between 40 and 70 percent receive 3-5 points; agencies with rates below 40 percent receive 0-2 points. Sub-component (b), Legal authority to withdraw conditional authorization for non-confirmation without requiring new evidence of patient harm (0-5 points). Sub-component (c), Automated commitment tracking and deviation detection infrastructure (0-4 points). Sub-component (d), Quality of specific post-market governance framework submitted with the application (0-3 points), encompassing clearly defined milestones, interim analysis checkpoints, and pre-specified regulatory consequences for milestone deviations. Compliance-as-Code automated governance pipelines demonstrate that automated commitment tracking substantially improves post-market milestone adherence rates (Oshoba, Ahmed, and Odejobi, 2023). Resilience and recovery models confirm automated monitoring system reliability in high-stakes governance contexts (Odejobi, Hammed, and Ahmed, 2023). AI- augmented secure software engineering confirms that AI-assisted safety signal detection achieves higher sensitivity than human review alone. Systematic review of incident investigation approaches confirms post-commitment monitoring requires structured investigation protocols (Obriki and Arumosoye, 2024). Supply chain automation framework confirms service management platform readiness for post-market monitoring at scale (Okonkwo et al., 2024c). Secure and scalable supply chain systems confirm reliability standards for regulatory monitoring platforms (Okonkwo et al., 2024d). National-scale supply chain optimisation provides reference for large-scale regulatory monitoring system design. Asset lifecycle management and inventory visibility confirms lifecycle tracking architectures applicable to post-market commitment monitoring (Okonkwo et al., 2023). 4.7 Dimension 6: Regulatory System Capacity (RSC, max 20) The Regulatory System Capacity dimension assesses the reviewing regulatory agency's operational capability to monitor post-market safety and effectiveness signals, conduct benefit- risk reassessments as confirmatory evidence accumulates, manage manufacturing compliance across the authorized product lifecycle, and initiate withdrawal proceedings within appropriate timelines when confirmatory evidence does not materialize. Five sub-components contribute: Sub- component (a), Pharmacovigilance system maturity against ICH E2E and WHO GVP standards (0-5 points): scored based on WHO GBT pharmacovigilance function maturity. Sub-component (b), Automated safety signal detection and expedited signal assessment infrastructure (0-4 points): scored based on documented operation of disproportionality analysis systems or equivalent for the agency's full portfolio. Sub-component (c), Manufacturing site inspection and compliance monitoring capacity for the specific manufacturing technology platform (0-4 points). Sub- component (d), Regulatory intelligence system quality for anticipating emerging regulatory science and safety developments (0-4 points). Sub-component (e), Documented capacity to maintain full regulatory functions during public health emergencies and operational disruptions (0-3 points). Emergency response readiness and capability model confirms RSC as a measurable, developable organizational property (Arumosoye and Obriki, 2023). Leading safety signals model confirms RSC leading indicator monitoring dimension. ESG performance through waste handling and operational discipline confirms environmental governance dimensions of RSC. Hazard identification advances and integrated safety management model confirm predictive monitoring and multi-zone governance capacity at highest RSC levels. Lifecycle performance evaluation of diagnostic laboratories and healthcare infrastructure investment outcomes confirm physical infrastructure and quantitative RSC assessment approaches (Ogbete et al., 2023; Ogbete and Aminu-Ibrahim, 2024). Infrastructure resilience planning confirms RSC stress-testing methodology for emergency capacity assessment. AI in modern agricultural systems provides AI- governance reference for digital RSC dimensions. Circular economy and renewable energy frameworks confirm sustainability governance and environmental technology RSC dimensions (Michael and Ogunsola, 2024a; Michael and Ogunsola, 2024b). Clinical record protection and digital operations models confirm information technology RSC dimensions (Nnaji and Akinlolu, 2024a; Nnaji and Akinlolu, 2024b). Healing-centered design confirms facility infrastructure RSC dimensions (Ogbete, Aminu-). Policy framework for chronic disease management confirms regulatory access linkages in RSC assessment. Emergency response coordination confirms RSC operational continuity dimensions. Table 1. RBAA-DM Six Dimensions: Full Specification, Sub-components, Scoring Anchors, and Pathway Implications Dimension (max 20) Sub-components Scoring Anchors , Selected Levels Pathway Designation Implication D1: Disease Severity & Burden (DS) Condition severity classification (max 8); unmet treatment gap index (max 7); patient burden quantification (max 5) DS 18-20: Immediately life- threatening, no acceptable alternative; DS 10-14: Serious, partial treatment options available; DS 0-6: Non-serious or adequately managed by existing therapies High DS supports Expedited or Priority pathway designation; low DS constrains to Standard pathway regardless of other scores D2: Unmet Medical Need Index Treatment option availability (max 8); response rate in current standard of care (max 7); access UMN 17-20: No or substantially inadequate existing treatment; UMN 10- 16: Available treatments with significant limitations; UMN 0-9: Adequate treatments High UMN is a necessary but insufficient condition for Accelerated pathway; must be paired with adequate EQS and PMCE scores equity dimension (max 5) available with incremental need D3: Evidence Quality & Surrogate Validity Surrogate endpoint validation tier (max 8); trial design quality (max 7); bridging evidence strength (max 5) EQS 16-20: Level I validated surrogate with established OS correlation; EQS 10-15: Level II surrogate with emerging mechanistic validation; EQS 0-9: Unvalidated or weakly supported surrogate EQS score determines whether Accelerated or Conditional pathway is scientifically justifiable; EQS below 10 with DS/UMN above 16 triggers Provisional Accelerated with mandatory Tier-1 post- market commitment D4: Benefit- Risk Profile Index Clinical benefit magnitude (max 8); safety signal characterisation (max 7); patient- reported outcomes alignment (max 5) BRI 16-20: Substantial clinical benefit with well- characterised safety; BRI 10- 15: Moderate benefit with manageable identified risks; BRI 0-9: Marginal benefit or serious unresolved safety signals BRI below 10 triggers rejection regardless of other scores; BRI 16+ combined with DS/UMN 16+ supports full Expedited pathway D5: Post- Market Commitment Enforceabilit y Sponsor confirmatory trial capacity (max 8); regulatory enforcement mechanism quality (max 7); withdrawal trigger governance (max 5) PMCE 16-20: Funded confirmatory trial already enrolled; robust withdrawal mechanism in national law; PMCE 10-15: Trial planned with regulatory milestone agreement; PMCE 0-9: No confirmatory trial capacity or withdrawal mechanism absent Low PMCE scores (below 8) generate mandatory Provisional classification with enhanced conditions regardless of pathway total D6: Regulatory System Capacity Post-approval surveillance infrastructure (max 8); regulatory workforce expertise (max 7); data governance maturity (max 5) RSC 16-20: WHO GBT Level 3-4 system with active pharmacovigilance; RSC 10- 15: GBT Level 2-3 with developing surveillance; RSC 0-9: GBT Level 1-2 with significant surveillance capacity gaps RSC below 10 triggers Provisional designation and mandatory capacity- building conditionality for all Expedited pathway decisions Dimension Max Sub-components (max scores) Min Threshold Score 8-13: Expedited Score 14-20: AA Supported DS: Disease Severity 20 (a) Life-threat 0-8; (b) Symptom burden 0-6; (c) Progression rate 0-3; (d) DALY burden 0-3 None (justification) Moderate urgency; may support Expedited Urgent patient access imperative; AA justification strong UMN: Unmet Need 20 (a) No effective therapy 0-8; (b) Pop. adequacy 0-6; (c) Patient PRO evidence 0-3; (d) Prescriber evidence 0-3 None (justification) Moderate gap; Priority Review warranted Substantial therapeutic gap; AA urgency confirmed EQS: Evidence Quality 20 (a) Surrogate validity Buyse 0-8; (b) Trial design ICH E8 0-6; (c) SAP pre-spec E6R3 0-3; (d) Data completeness 0-3 Min 8/20 for AA Established surrogate without Buyse; adequate design Validated surrogate R2>0.60; pre-specified SAP; complete data BRI: Benefit-Risk 20 (a) Effect size 0-7; (b) Subgroup consistency 0-5; (c) Adverse effects inv. 0-5; (d) Safety monitoring 0-3 Min 8/20 for AA Moderate effect; consistent safety; monitoring adequate Large consistent effect; favorable safety profile; excellent monitoring PMCE: Enforceability 20 (a) Track record 0-8; (b) Legal authority 0-5; (c) Auto monitoring 0-4; (d) Governance framework quality 0-3 Min 8/20 for AA Moderate enforcement history; some automation Completion rate >70%; statutory authority; full automation RSC: Reg. Capacity 20 (a) PV maturity 0-5; (b) Signal detection 0-4; (c) Mfg surveillance 0-4; (d) Intelligence quality 0- 4; (e) Continuity 0-3 Min 8/20 for AA Functional PV; partial automation; adequate surveillance Full lifecycle capacity; WHO GBT Level 4; predictive monitoring 5. Projected Decision Distribution and Expected Benefits Model 5.1 Projected Submission Score Distribution and Pathway Designation Outcomes The projected distribution of